- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
MEA
Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
Asia Pacific
Future Market Insights Global & Consulting Pvt. Ltd.
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market

Market Survey on ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment

An In-depth Market Insights of ESR1 Mutated Metastatic Breast Cancer Diagnostics Market including Tamoxifen, Aromatase inhibitors, Ovarian suppression, Fulvestrant, and Elacestrant Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others

Request Sample

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Snapshot

The global ESR1 mutated metastatic breast cancer diagnostics market garnered a market value of US$ 58.70 Million in 2022 and is expected to accumulate a market value of US$ 185 Million by registering a CAGR of 11% in the forecast period 2023 to 2033. Growth of the ESR1 mutated metastatic breast cancer diagnostics market can be attributed to increasing prevalence of breast cancer and the growing need for personalized treatment options for patients with specific genetic mutations. The market for ESR1 mutated metastatic breast cancer diagnostics market registered a CAGR of 6.9% in the historical period 2018 to 2022.

ESR1 is a gene that encodes for the estrogen receptor alpha protein, which plays a crucial role in regulating the growth and development of breast tissue. Mutations in this gene are found in approximately 30-40% of metastatic breast cancer patients and can lead to resistance to hormone therapy, a common treatment for breast cancer.

Diagnostics in this market may include genetic testing to detect ESR1 mutations, imaging tests to monitor disease progression, and other biomarker tests to aid in the diagnosis and treatment of ESR1 mutated metastatic breast cancer.

Report Attribute

Details

Expected Market Value (2023)

US$ 65.15 Million

Anticipated Forecast Value (2033)

US$ 185 Million

Projected Growth Rate (2023 to 2033)

11% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for ESR1 mutated metastatic breast cancer diagnostics reflected a value of 6.9% during the historical period, 2018 to 2022.

During this period, there were several advancements in the diagnostic tools and treatment options for ESR1 mutated metastatic breast cancer patients. In 2018, the FDA granted accelerated approval for a diagnostic test that can identify patients with ESR1 mutations who may benefit from a specific treatment. In 2019, the American Society of Clinical Oncology published updated guidelines for treating advanced breast cancer, highlighting the importance of genomic testing to identify patients with ESR1 mutations.

In addition, there were several key players in the market that made significant contributions to the development and commercialization of diagnostic tests for ESR1 mutated metastatic breast cancer. These included Myriad Genetics, Foundation Medicine, and Guardant Health.

Overall, the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market showed significant growth potential during the period between 2018 and 2021, with advancements in diagnostic tools and treatment options, but also faced challenges related to pricing and regulatory issues.

Thus, the market for ESR1 mutated metastatic breast cancer diagnostics is expected to register a CAGR of 11% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?

Increasing prevalence of breast cancer favoring growth of market

Breast cancer is one of the most commonly diagnosed cancers among women worldwide, and the incidence of breast cancer is increasing globally. As a result, there is a growing need for personalized treatment options for patients with specific genetic mutations such as ESR1 mutations.

There have been significant advancements in diagnostic technologies, including genetic testing, imaging, and biomarker analysis, which have enabled the identification of ESR1 mutations in breast cancer patients more accurately and quickly. The trend toward personalized medicine is growing, and there is a need for diagnostic tests that can identify specific genetic mutations in cancer patients to provide personalized treatment options that are tailored to each patient's individual needs.

There has been a significant increase in investment in research and development in the field of breast cancer diagnostics, including the development of new technologies and treatments for ESR1 mutated metastatic breast cancer patients. Regulatory approvals for diagnostic tests that can identify ESR1 mutations in breast cancer patients have increased, which has helped to drive the growth of the market.

Availability of diagnostic tools shaping landscape for ESR1 mutated metastatic breast cancer diagnostics market

Genetic testing: Genetic testing can be used to identify mutations in the ESR1 gene in breast cancer patients. These tests can be performed on tumor tissue or blood samples.

Imaging tests: Imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans can be used to monitor disease progression in breast cancer patients with ESR1 mutations.

Biomarker tests: Biomarker tests such as circulating tumor DNA (ctDNA) analysis can be used to monitor disease progression and response to treatment in breast cancer patients with ESR1 mutations.

Hormone receptor testing: Hormone receptor testing can be used to determine if a breast cancer patient has hormone receptor-positive breast cancer, which is a type of breast cancer that is often treated with hormone therapy.

Pathology testing: Pathology testing can be used to examine the tissue samples from a breast cancer biopsy to determine the type and stage of breast cancer and to identify ESR1 mutations.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?

Limited access to diagnostic tests along with regulatory challenges hampering market growth

The high cost of diagnostic tests and limited insurance coverage can limit patient access to these tests. Many healthcare providers may not be aware of the importance of genetic testing and other diagnostic tests for identifying ESR1 mutations in breast cancer patients.

There are currently limited targeted therapies available for the treatment of ESR1 mutated metastatic breast cancer, which can limit the impact of diagnostic testing. Regulatory hurdles can slow down the approval and adoption of new diagnostic tests and targeted therapies.

Technical challenges associated with genetic testing, including the complexity of the testing process and the need for specialized expertise and equipment, can limit the widespread adoption of these tests. Genetic testing raises ethical concerns, such as issues related to the privacy of genetic information and the potential for genetic discrimination. Thus, all the aforementioned factors are derailing the growth of ESR1 mutated metastatic breast cancer diagnostics market.

Region-Wise Insights

Robust Regulatory Framework Creating Lucrative Opportunities for North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?

Advancements in diagnostic technologies propelling growth of market in North America

Breast cancer is one of the most commonly diagnosed cancers in North America, and the incidence of breast cancer is increasing in the region. There have been significant advancements in diagnostic technologies, including genetic testing, imaging, and biomarker analysis, which have enabled the identification of ESR1 mutations in breast cancer patients more accurately and quickly.

The trend toward personalized medicine is growing in North America, and there is a need for diagnostic tests that can identify specific genetic mutations in cancer patients to provide personalized treatment options that are tailored to each patient's individual needs.

The regulatory framework for diagnostic tests in North America is robust, and there is a high level of scrutiny placed on new diagnostic tests, which helps to ensure their safety and efficacy. North America has one of the highest healthcare spending levels globally, and this has contributed to the growth of the market. Thus, North America is expected to possess 45% market share for ESR1 mutated metastatic breast cancer diagnostics market in 2023.

Increasing Healthcare Spending Favoring ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth in Europe?

Growing emphasis on personalized medicine boosting market growth in Europe

Breast cancer is one of the most common types of cancer in Europe, with an estimated 562,500 new cases diagnosed in 2020 alone. As breast cancer continues to be a major public health concern, the demand for advanced diagnostic tools like ESR1 mutated metastatic breast cancer diagnostics is expected to rise.

As medical research continues to uncover new information about breast cancer mutations, more healthcare providers are becoming aware of the importance of ESR1 testing. This increased awareness has led to greater demand for ESR1 mutated metastatic breast cancer diagnostics, as well as increased funding for research and development in this area.

Precision medicine aims to tailor treatment plans to each individual patient based on their unique genetic makeup. As more medical professionals adopt this approach, the demand for advanced diagnostic tools like ESR1 mutated metastatic breast cancer diagnostics is expected to rise.

Early detection and prevention are critical in the treatment of breast cancer. ESR1 mutated metastatic breast cancer diagnostics can play a key role in identifying mutations at an early stage, allowing for more effective treatment and better patient outcomes.

Thus, Europe is expected to possess 40% market share for ESR1 mutated metastatic breast cancer diagnostics market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Comprehensive Testing Making Diagnostic Centers go-to Option for ESR1 Mutated Metastatic Breast Cancer Testing?

Assurance of quality in diagnostics centers driving dependency for ESR1 Mutated Metastatic Breast Cancer Testing

Diagnostic centers often have a team of highly skilled and specialized healthcare professionals who have extensive experience in diagnosing and treating cancer, including breast cancer. Diagnostic centers typically have access to the latest imaging and diagnostic equipment, which can help to identify ESR1 mutations in breast cancer patients more accurately and quickly.

Diagnostic centers typically offer a comprehensive range of tests and procedures, including genetic testing, imaging, and biomarker analysis, which can help to identify ESR1 mutations in breast cancer patients and guide personalized treatment options.

Diagnostic centers often work closely with other healthcare providers, including oncologists, surgeons, and radiation therapists, to develop personalized treatment plans for breast cancer patients based on their specific needs.

Diagnostic centers often have strict quality assurance protocols in place to ensure that all tests and procedures are performed accurately and safely. Thus, diagnostic centers are expected to hold 47% market share for ESR1 mutated metastatic breast cancer diagnostics market in 2023.

Market Competition

Key players in the ESR1 mutated metastatic breast cancer diagnostics are Berlin-Chemie, Pfizer, Sanofi, G1 Therapeutics, Inc., Sun Pharma Advanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, Roche, AstraZeneca, Novartis, Zentalis Pharmaceuticals, Olema Pharmaceuticals

  • Berlin-Chemie has developed a diagnostic test called OnkoSelect ESR1 Mutation Test, which is used to identify ESR1 mutations in breast cancer patients. The OnkoSelect ESR1 Mutation Test is a PCR-based diagnostic test that detects the most common ESR1 mutations in breast cancer patients. The test is designed to be highly sensitive and specific, and it can be used with a range of different tissue samples, including formalin-fixed paraffin-embedded (FFPE) tissue samples.
  • Pfizer has developed a targeted therapy called palbociclib (brand name: Ibrance), which is used to treat advanced breast cancer, including ESR1 mutated metastatic breast cancer. Palbociclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that works by blocking the activity of proteins that promote cell division, thereby slowing or stopping the growth of cancer cells. The drug was approved by the US FDA in 2015 for the treatment of advanced breast cancer and has since been approved in several other countries around the world.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 65.15 Million

Market Value in 2033

US$ 185 Million

Growth Rate

CAGR of 11% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in USD Million and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • End User
  • Treatment
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Key Countries Profiled

  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA

Key Companies Profiled

  • Berlin-Chemie
  • Pfizer
  • Sanofi
  • G1 Therapeutics, Inc.
  • Sun Pharma Advanced Research Company
  • Zenopharm
  • Arvinas
  • Sermonix Pharmaceuticals
  • Roche
  • AstraZeneca
  • Novartis
  • Zentalis Pharmaceuticals
  • Olema Pharmaceuticals

Customization

Available Upon Request

Key Segments Profiled in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Survey

Hormonal therapy:

  • Tamoxifen
  • Aromatase inhibitors
  • Ovarian suppression
  • Fulvestrant
  • Elacestrant

Chemotherapy:

  • Capecitabine
  • Carboplatin
  • Cisplatin
  • Cyclophosphamide
  • Docetaxel
  • Others

Targeted therapy:

  • Monoclonal antibodies
  • Small molecule inhibitors
  • Tumor-agnostic treatments
  • Immunotherapy
  • Pembrolizumab
  • Dostarlimab

End User:

  • Hospitals
  • Clinics
  • Research and Academic Institutes
  • Diagnostic Centres

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

The projected revenue of the market by 2033 is US$ 185 million.

The market CAGR for 2033 is projected to be 11%.

The market is valued at US$ 65.15 million in 2023.

North America holds the largest market share.

The North American market is growing remarkably fast in the market due to the increasing incidence of breast cancer.

Table of Content

1. Executive Summary | ESR1 Mutated Metastatic Breast Cancer Diagnostics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Hormonal therapy

            5.3.1.1. Tamoxifen

            5.3.1.2. Aromatase inhibitors

            5.3.1.3. Ovarian suppression

            5.3.1.4. Fulvestrant

            5.3.1.5. Elacestrant

        5.3.2. Chemotherapy

            5.3.2.1. Capecitabine

            5.3.2.2. Carboplatin

            5.3.2.3. Cisplatin

            5.3.2.4. Cyclophosphamide

            5.3.2.5. Docetaxel

            5.3.2.6. Others

        5.3.3. Targeted therapy

            5.3.3.1. Monoclonal antibodies

            5.3.3.2. Small molecule inhibitors

            5.3.3.3. Tumor-agnostic treatments

        5.3.4. Immunotherapy

            5.3.4.1. Pembrolizumab

            5.3.4.2. Dostarlimab

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Research and Academic Institutes

        6.3.4. Diagnostic Centres

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Treatment

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Treatment

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Treatment

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Treatment

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By End User

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Treatment

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By End User

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Treatment

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By End User

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Treatment

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By End User

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Treatment

        14.2.3. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment

        14.3.3. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Treatment

            15.1.2.2. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Treatment

            15.2.2.2. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Treatment

            15.3.2.2. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Treatment

            15.4.2.2. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Treatment

            15.5.2.2. By End User

    15.6. United kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Treatment

            15.6.2.2. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Treatment

            15.7.2.2. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Treatment

            15.8.2.2. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Treatment

            15.9.2.2. By End User

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Treatment

            15.10.2.2. By End User

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Treatment

            15.11.2.2. By End User

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Treatment

            15.12.2.2. By End User

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Treatment

            15.13.2.2. By End User

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Treatment

            15.14.2.2. By End User

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Treatment

            15.15.2.2. By End User

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Treatment

            15.16.2.2. By End User

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Treatment

            15.17.2.2. By End User

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Treatment

            15.18.2.2. By End User

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Treatment

            15.19.2.2. By End User

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Treatment

            15.20.2.2. By End User

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Treatment

            15.21.2.2. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Treatment

        16.3.3. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Berlin-Chemie

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Pfizer

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Sanofi

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. G1 Therapeutics, Inc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Sun Pharma Advanced Research Company

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Zenopharm

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Arvinas

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Sermonix Pharmaceuticals

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Roche

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. AstraZeneca

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Novartis

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Zentalis Pharmaceuticals

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

        17.1.13. Olema Pharmaceuticals

            17.1.13.1. Overview

            17.1.13.2. Product Portfolio

            17.1.13.3. Profitability by Market Segments

            17.1.13.4. Sales Footprint

            17.1.13.5. Strategy Overview

                17.1.13.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 21: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 24: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by End User, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by End User, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by End User, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: South Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 70: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 71: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 73: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 74: South Asia Market Attractiveness by End User, 2023 to 2033

Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 89: East Asia Market Attractiveness by End User, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 92: Oceania Market Value (US$ Million) by End User, 2023 to 2033

Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 100: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 101: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 103: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 104: Oceania Market Attractiveness by End User, 2023 to 2033

Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 106: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 107: MEA Market Value (US$ Million) by End User, 2023 to 2033

Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 115: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 116: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 117: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 118: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 119: MEA Market Attractiveness by End User, 2023 to 2033

Figure 120: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Breast Cancer Drug Market

Published : July 2023

Healthcare

Breast Biopsy Market

Published : November 2022

Healthcare

Breast Biopsy Devices Market

Published : October 2022

Healthcare

Breast Lesion Localization Device Market

Published : May 2022

Explore Healthcare Insights

View Reports

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Cookie Policy